The effect of oral deferoxamine on iron absorption in humans.
Acute iron overdose is a serious cause of morbidity and mortality, however, optimal gastric decontamination procedures in iron overdose are unclear. In order to determine the effectiveness of oral deferoxamine mesylate solution in humans to prevent the absorption of iron in acute exposures, the following prospective case control crossover study was designed. Seven informed adult human volunteers were given an oral dose of 5 mg/kg elemental iron alone in a control phase and again in an experimental phase followed by a single equimolar dose of oral buffered deferoxamine solution. Plasma iron concentrations were determined spectrophotometrically for eight hours following administration of iron alone and following doses of iron with deferoxamine. There was no significant difference in peak iron concentration, time to peak iron concentration or area-under-the-curve between the two groups. Based on our results, equimolar doses of oral deferoxamine do not appear to decrease the absorption of low doses of oral iron in humans.
Jackson
T W
TW
Hennepin Regional Poison Center, Hennepin County Medical Center, Minneapolis, MN 55415, USA.
Ling
L J
LJ
Washington
V
V
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D003676:Deferoxamine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007501:Iron / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000506:poisoning; D008297:Male
D007501:Iron; D003676:Deferoxamine